As I said in my last post, decisions of medicines regulators can affect the share price of a pharmaceutical company.
A few recent examples – all from the past week:
The shares of Shires PLC sank 10% on Monday when the FDA approved a generic version of a competing drug.
The shares of Protalix BioTherapeutics Inc. dropped by 12% when the EMA recommended against a marketing authorisation for a drug being developed in cooperation with Pfizer (Pfizer shares remained the same.)
Shares in Celgene "tumbled" nearly 12% when the company withdrew an application to the European Medicines Agency “following a slew of questions” from the agency.
Bristol-Myers shares dropped 3.7%, while Pfizer was off 1.8% when the FDA blocked an application to market a new anti-clotting drug.
Share prices can also increase with a favourable opinion from a regulator.
Apart from the direct impact of regulatory decisions, many people in a regulatory agency, including non-executive support staff, may have access to “insider” or market-sensitive information. In other words they may know in advance of a decision that is likely to affect share prices.
So, back to my earlier point – rules or not, I believe it cannot be right for medicines regulators to hold shares in a pharmaceutical company.
BioTech, Consumers, Ethics in Business, EU Institutions, EU Priorities, Health, Health & Lifestyle, Innovation and Growth, Medicines, Pharmaceuticals, Public Affairs, Science & Research, Uncategorized